RxDoctor Payments Data

Robert Wilkerson, MD

Internal Medicine · Morrilton, ARNPI 1245322387

Payments from drug & device makers

$188in general payments, 2019–2025

Across 13 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$37
  • Astellas Pharma US Inc$35
  • Abbott$32
  • AbbVie$27
  • Pfizer$15
  • Novo Nordisk$15
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK3$37
Astellas Pharma US Inc2$35
Abbott2$32
AbbVie(2 entities)2$27
Pfizer1$15
Novo Nordisk1$15
Amgen1$14
E.r. Squibb & Sons, L.L.C.1$13

How this compares

$188 in reported general payments places this provider in the 45th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$22,987
Medicare patients
647
Services billed
1,985

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban180$104,336
XareltoRivaroxaban44$32,866
OzempicSemaglutide33$29,850
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$17,016
LinzessLinaclotide26$13,898
Breo ElliptaFluticasone/Vilanterol20$12,948
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog36$11,570
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen243$6,569
Bevespi AerosphereGlycopyrrolate/Formoterol Fum14$5,761
Tresiba Flextouch U-100Insulin Degludec11$4,946
Novolin NInsulin Nph Human Isophane15$3,681
Potassium Chloride243$3,508
Levothyroxine Sodium320$3,244
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$3,198
Omeprazole286$2,323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$104,336180 claims
GSKTrelegy Ellipta, Breo Ellipta$37$29,96444 claims
Novo NordiskOzempic$15$29,85033 claims
AbbVieLinzess, Synthroid$27$15,35758 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Morrilton

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →